|Aeterna Zentaris Inc.|
1405 du Parc-Technologique Boulevard
QC G1P 4P5
Canada - Map
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.
|Mr. David Alan Dodd ,
Chairman, Chief Exec. Officer and Pres
|Mr. Keith Santorelli CPA,
Chief Accounting Officer and VP of Fin.
|Dr. Richard Sachse M.D., Ph.D.,
Chief Scientific Officer, Chief Medical Officer and Sr. VP
|Mr. Jude Dinges ,
Chief Commercial Officer and Sr. VP
|Mr. Philip A. Theodore ,
Chief Admin. Officer, Sr. VP, Gen. Counsel and Corp. Sec.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|